Led · Equity · Jun 2026

Wheere develops a geolocation system capable of penetrating up to 50 m of concrete and covering a square kilometer with a small number of transmitters. Its terrestrial technology is reported to be 95% operational and the company has started commercial deployments and proofs of concept with industrial customers such as EDF, TotalEnergies and L’Oréal. Wheere projects €1M revenue in 2026 from ongoing POCs and forecasts €2.5M in 2027 while scaling through integrator partners and international deployments. Strategically, the company plans to launch space demonstrators beginning February 2027 on an Exotrail bus and expand into a constellation (65 satellites by end-2029, 300 by 2031) to enable global coverage. Wheere is also investing in miniaturization to produce a low-cost component that captures terrestrial and satellite signals, shifting future monetization toward services rather than hardware.

Participated · Equity · May 2026

Founded in 2022 and based in Montpellier, ThIA Santé Mentale develops a coordinated model of care in mental health that pairs digital and organizational solutions with clinical partners. The company positions itself in psychiatry, working with practitioner partners to deliver coordinated care pathways. In May 2026 it secured a €5M funding round led by institutional and insurance investors to scale that model. Investors in the round include IRDI Capital Investissement, Sofilaro Innovation, Generali, AG2R La Mondiale, and participating individual and practitioner investors. The stated use of proceeds is to extend and scale its coordinated care offering. The articles do not provide revenue, user metrics, or a valuation.

Participated · Equity · Mar 2026

DiappyMed builds a digital therapy designed to personalize insulin dose calculations for people with type 1 or type 2 diabetes treated with a basal/bolus regimen. The company presents its solution as the first French therapy numérique dedicated to individualized insulin dosing and says it works with professionals de santé and patients. DiappyMed announced a strategic partnership with Sanofi to enable broad deployment of the therapy across France. The company aims to secure reimbursement from Assurance Maladie by 2026 and frames the recent financing and partnership as steps toward that objective. In support of its rollout, DiappyMed raised €5 million in an amorçage round led by Ventech and AFI Ventures with participation from SOFILARO/CALEN and IRDI Capital Investissement, and cited additional institutional partners and supporters. No revenue, user metrics, founding year, or valuation were disclosed in the available articles.

Participated · Equity · Dec 2025

Founded in May 2023 by Nicolas Navarro, APS (Agnostic Production Systems) is building APS CONTROL®, an ecosystem of plug-and-play industrial modules that automatically orchestrate people, machines and existing software within production sites. The product is anchored in the patented Connect and Produce® technology and is designed to be faster, cheaper and lower-risk than traditional manufacturing execution system integrations. Targeting the 26,600 French SMEs and ETIs that have largely been left out of Industry 4.0, APS aims to accelerate the shift toward more agile, sustainable and resilient factories. The company collaborates with the CEA and the CERIS research center (IMT Mines Alès) and plans to launch APS CONTROL® commercially in summer 2026. APS already employs more than 20 people and continues to recruit. Prior to the current equity raise, it secured support from Bpifrance and CRÉALIA Occitanie and non-dilutive bank financing from Banque Populaire du Sud, Caisse d’Épargne Languedoc-Roussillon and the Banque de l’innovation du Crédit Agricole du Languedoc.

Participated · Series A · Dec 2025

Sim&Cure is a med-tech software company dedicated to making neurovascular procedures safer and more effective through personalised simulation technology. Its flagship product, Sim&Size, builds a digital twin of each patient, allowing clinicians to model multiple endovascular treatment scenarios before intervention; the tool has already been used by more than 700 healthcare professionals in over 45 countries to plan upwards of 35,000 procedures. The firm is broadening its offering with Sim&Train, a 3D-printing-based training platform, and Sim&Predict, an AI application that automatically detects cerebral aneurysms on medical images. Partnerships with Siemens Healthineers and Philips aim to integrate these simulation capabilities directly into leading imaging ecosystems. Fresh capital will be channelled into accelerating R&D, expanding the commercial team, and driving international growth, particularly in China and the wider Asia-Pacific region. Although revenue figures were not disclosed, the extensive clinical uptake underscores significant commercial momentum. The company intends to use its growing software portfolio to promote a preventive and personalised approach to aneurysm management worldwide.